

SPONSORSHIP AGREEMENT

This sponsorship agreement (the “**Agreement**”) is made effective as of 29. February 2024 (the “**Effective Date**”), between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby. CVR nr. 19 17 90 79 (“**Sobi**”) and and Sjøaldne Diagnoser, Blekinge Boulevard 2, DK-2630 Taastrup (“**Recipient**”).

The above Parties may also be referred to jointly as the “**Parties**” and individually as “**Party**”.

WHEREAS, Sobi A/S is an affiliate of an international biopharmaceutical company dedicated to rare diseases;

WHEREAS, Recipient is ; Rare Diseases Denmark is a national alliance of 55 rare disease societies. Rare Diseases Denmark’s work is based on volunteers and a minor professional secretariat. Rare Diseases Denmark was founded in 1985 under the name KMS – The Danish Association for Rare Diseases.

WHEREAS, Sobi has agreed to give a sponsorship of 15.000 DKK to the Rare Disease Day 2024 at 29. February 2024 or Event] (the “**Event**”) on the terms and conditions set out below.

NOW, THEREFORE, the parties agree as follows:

1. TERMS AND CONDITIONS OF SPONSORSHIP

- 1.1 Sponsorship: Sobi hereby agrees to sponsor the Event by paying the total amount of fifteen thousand 15.000 DKK + applicable VAT for the purpose of the sponsorship as specified in Schedule 1. (the “Sponsorship”).
- 1.2 Scope: The Sponsorship shall only cover actual, documented, reasonable and direct costs that are necessary in order to carry out the Meeting, as further specified in Schedule 1. Recipient warrants that Sobi’s support under this Agreement shall be used solely for the Sponsorship in compliance with this Agreement, that the Sponsorship and Event will be carried out in accordance with all applicable laws, regulations and in-dustry code requirements, including without limitation, any transparency regula-tions and disclosures (“Applicable Law”) and that any activities performed and ma-terials generated in connection with the Event shall comply with Applicable Law.
- 1.3 Follow-up and Repayment: Within thirty (30) days of the Event, Recipient shall provide Sobi with a signed declaration that the Event has taken place and the funds provided under the Sponsorship used in full in accordance with the terms

of this Agreement or inform Sobi if any funds provided remain. Recipient undertakes to repay refundable parts of the Sponsorship if the Event is cancelled, if this Agreement is terminated pursuant to Section 3.5 or if there are any remaining funds after the Event. Such payment shall be made within thirty (30) days of the cancellation, termination or Event.

- 1.4 Benefits of Sponsorship: In return for Sobi sponsoring the Meeting Recipient shall provide Sobi with the benefits specified in Schedule 2.
- 1.5 Payment:
- 1.6 The Sponsorship will be paid as specified in Schedule 1.
- 1.7 Payment Terms: All payments hereunder shall be made within thirty (30) days via bank transfer or from receipt of invoice provided that the following conditions shall have been met: invoices shall be specified as to Sobi contact person Mia Enochen. Sobi's invoice address is: Sobi, Sorgenfrivej 17, 2800 Lyngby.
- 1.8 Use of Sobi name: Recipient shall only use the name and logotypes of Sobi, in publications, presentations, programmes, other printed or orally presented materials or otherwise, after prior review and approval of Sobi.
- 1.9 Publication of Sponsorship: Recipient undertakes to declare that the Event has been sponsored by Sobi whenever any written or oral information is shared in public about the Event. If Recipient has a website, then this shall include publishing information of the Sponsorship on its website. Sobi may use the name or logo of Recipient to publish the Sponsorship on its website, as well as reporting it to all local governing bodies, as appropriate, in accordance with transparency requirements
No inducement: Recipient acknowledges that provision of the Sponsorship is in no way an inducement to recommend, prescribe, purchase, supply, sell or administer a particular medicinal product.
- 1.10 Hospitality, programme and venue of the Meeting: The Recipient represents and warrants to Sobi that
 - (a) Hospitality made directly or indirectly available during the Meeting shall be kept at a reasonable level and remain secondary to the principal scientific purpose of the Meeting, be limited to the organisation and/or defrayment of the costs of travel, meals, accommodation and registration, shall not extend beyond the official duration of the Meeting and shall not include payment for or the organization of sports or leisure activities or any other form of entertainment;
 - (b) The value of meals provided, drinks included, shall not exceed the limits

laid down by Applicable Law, including applicable local industry guidelines;

(c) The Meeting shall be predominantly scientific in nature and activities with a scientific purpose shall, in terms of time, take up the greater part of each day of the Meeting; and

(d) The Meeting shall take place at a suitable venue that aids the scientific purpose of the event and the place, date and duration of the Meeting and travel shall not in any case be of a nature to create any uncertainty as to its scientific nature.

(e) Where applicable, a positive e4ethics assessment has been obtained for the Event, as required under the EFPIA Code, a copy of which shall upon request be provided to Sobi.

2. DATA PRIVACY AND TRANSPARENCY

2.1 EU privacy law requires that Sobi provide Recipient and/or its representative(s) notice that Sobi and its group companies may collect, use and retain such representatives' personal data (e.g. name and contact details) provided in this contract Agreement for administration, reimbursement, and internal evaluation purposes. Sobi will process the personal data to the extent necessary to fulfil Sobi's duties under this contract Agreement and for the purpose of Sobi's legitimate interest as contractor. Sobi may share the representatives' personal data within the Sobi group and with Sobi service providers and agents for the purposes stated in this Section 3.1. Such sharing may include transfer to third countries, i.e. countries outside the EU/EESA area. When transferring the representatives' personal data to third countries, Sobi will ensure that the transfer is subject to appropriate safeguards and that the representatives' rights are protected. Typically, Sobi will enter into standard contractual clauses adopted by the eu commission with companies in third countries receiving personal data from Sobi. Sobi applies different retention periods for different categories of personal data. When processing of the repre-sentatives' personal data is no longer necessary in relation to the purpose for which it was collected Sobi will erase the personal data. The representatives have the right to access the personal data that Sobi processes concerning the repre-sentatives and to request that Sobi rectifies any inaccurate personal data and un-der certain circumstances request erasure and/or restriction of processing of the personal data. The representatives have the right to object to processing and to receive the processed personal data in a structured, commonly used and machine-readable format and has the right to transmit those data to another controller. The representatives also have the right to lodge a complaint to the local supervisory authority ("Datatilsynet") regarding

how Sobi processes such representatives' personal data. Recipient undertakes to share the information provided in this Section 2.1 with all representatives engaged by Recipient or on its behalf in connection with this Agreement and whose personal data will be shared with Sobi..

- 2.2 "Parties"/"Party" further acknowledges and agrees that Sobi has an annual reporting obligation to ENLI (Ethical Committee for the Pharmaceutical Industry) about the HCO/PO they have had a relationship with during the year.
- 2.3 In addition, "Parties"/"Party" acknowledges and agrees that Sobi documents all relationships required to be disclosed with ENLI and maintains the relevant records of the disclosures for a minimum of 5 years after the end of the relevant reporting period (unless a shorter period is required under applicable national data privacy or other laws or regulations). Thereafter the data will be deleted by Sobi.

3. MISCELLANEOUS

- 3.1 **Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements of the parties with respect to such subject matter
- 3.2 **Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement.
- 3.3 **Assignments:** This Agreement is personal to the parties who shall not have any right to assign it without the prior written consent of the other party, except that Sobi shall have the right to assign the Agreement to its affiliates.
- 3.4 **Independent Contractors:** In making and performing this Agreement, the parties are acting and shall act at all times as independent contractors, and nothing contained in this Agreement shall be construed or implied to create any agency, partnership or employer and employee relationship between Sobi and Recipient. At no time shall any party make commitments or incur any charges or expenses for or in the name of any other party, other than as expressly set forth herein.
- 3.5 **Termination:** Without limiting any rights or remedies under the governing law pursuant to Section 2.7, Sobi is entitled to terminate this Agreement at any time with immediate effect if in Sobi's reasonable opinion the PCO and/or the HCO commits a material breach of any of its undertakings pursuant to this Agreement,

in which case the PCO promptly shall see to it that all references to Sobi are removed from any Meeting announcements and materials.

- 3.6 Survival: Sections 1.3, 1.9, 2.6, 2.7, 2.8, 3.2 shall survive the termination or expiration of this Agreement.
- 3.7 Governing Law: This Agreement shall be governed and construed by the substantive laws of Denmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country..

[Signatures to follow on the next page.]

In Process
In Process

This Agreement has been signed by each Party's duly authorized signatory(ies). This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original and all of which shall constitute together one and the same document. The Parties agree that the execution of this Agreement by electronic means using standard industry signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and in any proceeding arising under or relating to this Agreement, each Party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed Agreement electronically.

Swedish Orphan Biovitrum A/S

Rare Diseases Denmark

DocuSigned by:
Mia Enochsén
E88695B007694FF...

Name: Mia Enochsén
Title: Country Manager Denmark/Iceland
Date: 16-Nov-23

Name: Lene Jensen
Title: Director
Date:

:

SCHEDULE 1

SPONSORSHIP AND COSTS

Sobi Denmark has agreed to give a sponsorship of 15.000 DKK to Rare Diseases Denmark for the Rare Disease Day February 29, 2024.

The grant will cover a part of the expenses for materials used during the rare march in public on February 29, 2024.

In Process
In Process

SCHEDULE 2

BENEFITS OF THE SPONSORSHIP

Sobi will have the benefit of being mentioned with name and link to Rare Diseases Denmark's homepage for the Rare Disease Day and will be invited to participate with one representative at the activities arranged in Copenhagen on February 29, 2024.

In Process
In Process

Certificate Of Completion

Envelope Id: 904C94DFC28A4BFDAFCF8B216A756EFA	Status: Delivered
Subject: Sponsorship Rare Disease Day 29. February 2024	
Source Envelope:	
Document Pages: 8	Signatures: 1
Certificate Pages: 5	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Enabled	Sobi
Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London	Corunna House, 39 Cadogan Street
	Glasgow, Lanakshire G2 7AB
	cpai@sobi.com
	IP Address: 20.54.13.189

Record Tracking

Status: Original	Holder: Sobi	Location: DocuSign
11/15/2023 12:17:41 PM	cpai@sobi.com	

Signer Events

Mia Enochsen
mia.enochsen@sobi.com
Country Manager, Denmark & Iceland
Security Level: Email, Account Authentication (None)

Signature

DocuSigned by:

E88695B007694FF...
Signature Adoption: Pre-selected Style
Using IP Address: 94.189.60.206

Timestamp

Sent: 11/15/2023 12:18:37 PM
Viewed: 11/16/2023 9:16:56 AM
Signed: 11/16/2023 9:17:11 AM

Electronic Record and Signature Disclosure:

Accepted: 11/16/2023 9:16:56 AM
ID: f417ea9d-3db1-428c-95b3-f3b24be4930c
Company Name: ContractPodAi

Lene Jensen
lj@sjaeldnediagnoser.dk
Security Level: Email, Account Authentication (None)

Sent: 11/16/2023 9:17:13 AM
Viewed: 11/16/2023 10:05:42 AM

Electronic Record and Signature Disclosure:

Accepted: 11/16/2023 10:05:42 AM
ID: 65a40353-b942-45f1-bae4-2cd03d318d5a
Company Name: ContractPodAi

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	11/15/2023 12:18:37 PM
Certified Delivered	Security Checked	11/16/2023 10:05:42 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

In Process
In Process

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, the sending company (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your DocuSign, Inc. (DocuSign) Express user account. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. For such copies, as long as you are an authorized user of the DocuSign system you will have the ability to download and print any documents we send to you through your DocuSign user account for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of your DocuSign account. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use your DocuSign Express user account to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through your DocuSign user account all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact the sending company:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: help@contractpodai.com

To advise the sending company of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at help@contractpodai.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in DocuSign.

To request paper copies from the sending company

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to help@contractpodai.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with the sending company

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign account, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to help@contractpodai.com and in the body of such request you must state your e-mail, full name, IS Postal Address, telephone number, and account number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows2000? or WindowsXP?
Browsers (for SENDERS):	Internet Explorer 6.0? or above
Browsers (for SIGNERS):	Internet Explorer 6.0?, Mozilla FireFox 1.0, NetScape 7.2 (or above)
Email:	Access to a valid email account
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	<ul style="list-style-type: none">• Allow per session cookies

- | | |
|--|---|
| | <ul style="list-style-type: none">• Users accessing the internet behind a Proxy Server must enable HTTP 1.1 settings via proxy connection |
|--|---|

** These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time providing you with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I Agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC RECORD AND SIGNATURE DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify the sending company as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the sending company during the course of my relationship with you.